For Advanced Ewing Sarcoma, Olaparib Alone Not Effective
the Cancer Therapy Advisor take:
According to a new study published in the journal BMC Cancer, researchers have found that olaparib, a novel poly ADP ribose polymerase (PARP) inhibitor, was safe but not effective for the treatment of patients with advanced Ewing sarcoma who have progressed after standard chemotherapy.
For the phase 2 study, researchers sought to investigate the use of olaparib in patients with Ewing sarcoma after preclinical trials showed antitumor activity with olaparib against Ewing sarcoma cells. Researchers enrolled 12 adult patients with radiographically measurable metastatic Ewing sarcoma and each participants received olaparib 400mg orally twice daily until disease progression or unacceptable toxicity.
Researchers measured tumor size by CT or MRI at 6 and 12 weeks after olaparib administration, followed by every 8 weeks. Results showed no complete or partial responses. Four patients had stable disease and eight patients had progressive disease at best response. The median duration to disease progression was 5.7 weeks. Therefore, researchers discontinued further enrollment.
Adverse effects with olaparib were similar with other studies that have investigated the PARP inhibitor.
Despite the lack of efficacy with olaparib alone, other studies are currently investigating the use of olaparib in combination with cytotoxic chemotherapy for the treatment of adult patients with Ewing sarcoma.
Olaparib was safe but not effective for the treatment of patients with advanced Ewing sarcoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer